Mark Neumann - 01 Mar 2023 Form 4 Insider Report for Intra-Cellular Therapies, Inc. (ITCI)

Role: EVP, Chief Commercial Officer
Signature: /s/ Lawrence J. Hineline, Attorney-in-fact
Issuer symbol: ITCI
Transactions as of: 01 Mar 2023
Net transactions value: -$362,122
Form type: 4
Filing time: 03 Mar 2023, 18:03:35 UTC
Previous filing: 27 Feb 2023
Next filing: 08 Mar 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ITCI	Common Stock	Sale	$362,122	-7,241	-13%	$50.01	49,199	01 Mar 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2022.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.495, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.

Content

This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2022.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.495, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.